中文名 | 黄芪甲甙 IV |
英文名 | Astragaloside IV |
别名 | 黄芪甙 黄芪甲甙 黄芪甲苷 黄芪皂苷Ⅳ 黄芪皂苷IV 黄芪甲苷IV 黄芪甲苷 IV 黄芪甲甙 IV 黄芪皂苷XIV 黄芪甲苷(分析标准品) 黄芪甲苷, 来源于黄岑 黄芪提取物(黄芪甲苷) |
英文别名 | astragalosideⅣ Astragaloside IV Astrasieversianin XIV 20,24-epoxy-16,25-dihydroxy-3-(β-D- β-D-Glucopyranoside, (3β,6α,16β,20R,24S)- xylopyranosyloxy)-9,19-cyclolanostan-6-yl beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl (5xi,6beta,8xi,9xi,16alpha,20R,24S)-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-20,24-epoxy-9,19-cyclolanostan-6-yl beta-D-glucopyranoside |
CAS | 84687-43-4 |
EINECS | 1532714-185-1 |
化学式 | C41H68O14 |
分子量 | 784.97 |
InChI | InChI=1/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20-,21-,22-,23?,24?,25+,26+,27-,28+,29-,30-,31+,32?,33+,34-,37-,38+,39-,40?,41-/m1/s1 |
InChIKey | QMNWISYXSJWHRY-BTUAQNSKSA-N |
密度 | 1.39 |
熔点 | 295-296°C |
沸点 | 895.7±65.0 °C(Predicted) |
比旋光度 | +24.4°(c=0.23,methanol) |
闪点 | 495.5°C |
蒸汽压 | 0mmHg at 25°C |
溶解度 | 甲醇 (微溶,超声处理),吡啶 (微溶) |
折射率 | 1.62 |
酸度系数 | 12.91±0.70(Predicted) |
存储条件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
外观 | 整洁 |
颜色 | White to Off-White |
物化性质 | 来源于豆科黄芪的根。 |
MDL号 | MFCD16036240 |
安全术语 | S22 - 切勿吸入粉尘。 S24/25 - 避免与皮肤和眼睛接触。 |
WGK Germany | 3 |
海关编号 | 29389090 |
参考资料 展开查看 | 1. 张素清 陈冰 陈思邈 等. R语言与正交试验分析处理优化黄芪中黄芪甲苷提取工艺的比较[J]. 中国中医急症 2020(8). 2. 袁一凡 陈晓月 刘保霞 刘笑 李瑞宏 祁金龙 贾庆忠.UPLC-MS/MS法同时测定康艾注射液中11种成分[J].中草药 2017 48(13):2660-2665. 3. 陈开, 周静, 李敏,等. 基于大孔树脂的黄芪中黄芪甲苷提取液纯化工艺研究[J]. 中国中医急症, 2017, 26(011):1881-1883. 4. 孙铭忆, 李冰韶, 王永洁,等. 基于模糊层次分析法优选复方黄芪水浸膏提取工艺路线[J]. 中草药, 2018. 5. 孟琦, 宝丽, 张烨,等. 基于肠道菌群调节的小檗碱和黄芪甲苷联用降糖机制研究[J]. 食品与药品, 2020(3):169-175. 6. 李玉美, 陈新梅, 徐溢明,等. 纳秒脉冲电场灭菌对舒心糖浆质量影响的初步研究[J]. 化工时刊, 2015(04):31-32+52. 7. 倪琳, 魏学冰, 陈德道,等. 黄芪乌梅降糖颗粒的制备工艺与质量分析[J]. 海峡药学, 2020, v.32;No.240(01):10-15. 8. 朱易平, 李茹柳, 时玉霞,等. 黄芪总皂苷对IEC-6细胞增殖及相关蛋白表达的影响[J]. 中药新药与临床药理, 2019, 30(01):60-65. 9. 武建毅, 沈清, 金赟洁,等. 黄芪甲苷对BALB/C小鼠肝癌H22腹水瘤抑制作用及机制[J]. 中国药物警戒, 2016, 13(003):138-142. 10. 张吉, 臧东钰. 黄芪甲苷对急性肺损伤大鼠内质网应激介导影响[J]. 中国民族民间医药, 2014, 000(015):19-20. 11. 赵彩萍,刘翠玲,梁爽,李欣蓉,柳雪蕾,朱美玲.黄芪甲苷对脂多糖诱导人胃黏膜上皮细胞GES-1的抗炎作用及机制研究[J].中药新药与临床药理,2020,31(08):918-923. 12. 熊莉,吕梦娟,窦德宇,马玉红.黄芪甲苷对血管紧张素Ⅱ诱导肾小球系膜细胞增殖及炎症因子表达的影响[J].中国应用生理学杂志,2018,34(05):414-417+421. 13. 贾力维, 沃晓嫚, 王谦博,等. 黄芪甲苷对非小细胞肺癌A549细胞增殖及凋亡相关蛋白表达的影响[J]. 黑龙江大学自然科学学报, 2019, 036(001):84-89. 14. 刘晨旭,张玫,杨洋,魏鹏翔,魏群利.黄芪甲苷对高糖诱导下大鼠肾小球系膜细胞TGF-β1/Smad信号通路的影响[J].徐州医科大学学报,2019,39(09):641-643. 15. 俞曼殊, 史俊, 赵君谊,等. 黄芪甲苷调控Akt信号通路阻抑人腹膜间皮细胞间充质转化的实验研究[J]. 南京中医药大学学报, 2019, 35(01):53-57. 16. 张怡, 靳晓飞, 周晓红,等. 黄芪甲苷调控自噬抑制缺氧缺糖/复氧复糖HT22细胞凋亡[J]. 中国药理学通报, 2019, 035(004):519-524. 17. 张悦,于学炜,于宏川,仲伟一,杨阳.黄芪甲苷调节miR-21基因抑制肾癌细胞增殖和诱导细胞凋亡的机制探讨[J].现代肿瘤医学,2020,28(18):3145-3150. 18. 成鹏,白银亮,胡彩莉,连佛彦,周海宇.黄芪甲苷通过调控FoxO3a/Wnt2/β-catenin通路抑制去卵巢大鼠骨质疏松的作用[J].中国实验方剂学杂志,2018,24(15):161-166. 19. 李杨, 郭超, 张小平,等. 黄芪皂苷-氢氧化铝佐剂复合物对bFGF肿瘤疫苗抗乳腺癌活性的影响[J]. 河西学院学报, 2018, 34(05):32-37. 20. 韦赫, 程林, 吴培,等. 黄芪皂苷生物合成对短期水分变化的响应[J]. 中国中药杂志, 2019, 44(03):39-45. 21. 何昊 许畅 王兴中 苏力 张家旭. 四种不同方法提取黄芪中黄芪甲苷的对比研究[J]. 化工科技(3期):25-28. 22. 李富欣, 于蓓蓓, 刘瑾,等. 茯黄颗粒的质量标准研究[J]. 西部中医药, 2019, 032(002):P.44-48. 23. 邹龙 刘辉 李仲秋 等. HPLC测定补阳还五汤总苷中黄芪甲苷和芍药苷的含量[J]. 湖南中医药大学学报 2012 32(005):39-42. 24. 邹龙, 李欢欢, 刘辉,等. 补阳还五汤总苷胶囊的制备工艺优选. 中国实验方剂学杂志. 25. 张婕,梁程程,杨爱仲,齐聪.增免抑瘤方及有效组分对卵巢癌干细胞裸鼠移植瘤Notch/Jagged1信号通路的影响[J].中国实验方剂学杂志,2020,26(15):46-53. 26. 燕玉奎, 郭玫, 邵晶,等. 红芪及其不同提取部位中主要活性成分的含量测定[J]. 中兽医医药杂志, 2020, v.39;No.220(01):22-25. 27. 支旭然 刘洪涛 吴茵 等. UPLC-MS/MS法同时测定肾康注射液中7个有效成分[J]. 药物分析杂志 2017 037(001):37-42. 28. 张素清,陈冰,陈思邈,董静怡,陈伟燕,张宇燕.R语言与正交试验分析处理优化黄芪中黄芪甲苷提取工艺的比较[J].中国中医急症,2020,29(08):1420-1423. 29. 孙乐,吴鹏,王春艳,张学兰,金玉翠,刘海滨.黄芪饮片炮制工艺优选[J].时珍国医国药,2020,31(07):1616-1619. 30. 赵宏月,张东伟,庞琳琳,张欢,于睿.黄芪甲苷及人参皂苷Rg1对高脂大鼠心肌缺血再灌注损伤后心肌细胞凋亡的影响[J].辽宁中医杂志,2021,48(02):188-191. 31. 冯紫薇. 子洲黄芪饮片质量等级标准研究[D].北京中医药大学,2020. 32. 姚萱航,刘翠晶,常晶茹,张雪薇,刘霞.2种类型膜荚黄芪主要药效成分含量及关键酶基因表达量差异研究[J].中草药,2021,52(07):2072-2081. 33. 程欢,米雅慧,刘明平,于洋,黎同明.黄芪多糖、黄芪甲苷对大黄酸肠吸收的影响[J].中药新药与临床药理,2021,32(02):240-244. 34. 冯美杰,李蕾,王颖航,徐兢鸿,潘志.黄芪甲苷对人类风湿关节炎成纤维样滑膜细胞增殖及白细胞介素6分泌的影响[J].中国中医基础医学杂志,2020,26(10):1484-1487. 35. 彭胜男,陶琰心,洪婷,杨海燕,黄青.黄芪甲苷通过mTORC1通路调控IgA肾病大鼠脾淋巴细胞分化[J].中国免疫学杂志,2021,37(04):421-425. 36. 曾广伟,安慧仙,方东,高钊,贾建军,朱舜明.黄芪甲苷抑制缺血再灌注诱导的大鼠心肌细胞凋亡[J].现代生物医学进展,2020,20(24):4612-4617. 37. 张悦,于学炜,于宏川,仲伟一,杨阳.黄芪甲苷调节miR-21基因抑制肾癌细胞增殖和诱导细胞凋亡的机制探讨[J].现代肿瘤医学,2020,28(18):3145-3150. 38. 彭胜男,陶琰心,洪婷,杨海燕,黄青.黄芪甲苷通过mTORC1通路调控IgA肾病大鼠脾淋巴细胞分化[J].中国免疫学杂志,2021,37(04):421-425. 39. 徐芳芳,张秀莉,侯滔,曲腊腊,王纪霞,刘艳芳,梁鑫淼.天然产物中FFA1受体新激动剂的发现与研究[J].上海中医药大学学报,2021,35(01):12-19.[4]宫梦琪,孙倩,李振.天麻中天麻素提取工艺优化及抑制α-葡萄糖苷酶活性研究[J].中国果菜,2020,40(09):14-17+23. 40. 田文仓. 不同生长年限及采收期子洲黄芪鉴别特征及其质量、产量差异分析[D].北京中医药大学,2020. 41. 范小龙,陈冉,吴婉琴,刘国姣,黄坤,江丰.液相色谱串联质谱法测定食品中淫羊藿苷等20种功能成分[J].食品与机械,2021,37(01):86-93+98. 42. Wang, Xiaoping, et al. "Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats." Journal of ethnopharmacology 252 (2020): 112536.https://doi.org/10.1016/j.jep.2019.112536 43. Liu, Tongji, et al. "Improvement effect of lotus leaf flavonoids on carbon tetrachloride-induced liver injury in mice." Biomedicines 8.2 (2020): 41.https://doi.org/10.3390/biomedicines8020041 44. Ting Liu, Jin-Xi Liao, Yang Hu, Yuan-Hong Tu, and Jian-Song SunThe Journal of Organic Chemistry 2017 82 (8), 4170-4178DOI: 10.1021/acs.joc.7b00080 45. Fan, Qiangyuan, et al. "Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: preparation by supercritical fluid technology and evaluation in vitro and in vivo." International journal of pharmaceutics 552.1-2 (201 46. Yang, Jing-Jing, et al. "Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells." Nutrition, Metabolism and Cardiovascular Diseases 30.5 (2020): 829-842.https://doi.org/10.1016/j.numecd.2020.01.00 47. [IF=7.514] Yuping Zhang et al."Integration of magnetic solid phase fishing and off-line two-dimensional high-performance liquid chromatography–diode array detector–mass spectrometry for screening and identification of human serum albumin binders from Radix Astragali 48. [IF=4.759] Yuping Zhang et al."On-line surface plasmon resonance-high performance liquid chromatography–tandem mass spectrometry for analysis of human serum albumin binders from Radix Astragali."J Chromatogr A. 2013 Jun;1293:92 49. [IF=4.354] Ting Liu et al."Synthetic Access Toward Cycloastragenol Glycosides."J Org Chem. 2017;82(8):4170–4178 50. [IF=4.213] Qiangyuan Fan et al."Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo."Int J Pharmaceut. 2018 Dec;552:360 51. [IF=3.098] Xiao Chen et al."Astragaloside IV ameliorates high glucose‑induced renal tubular epithelial‑mesenchymal transition by blocking mTORC1/p70S6K signaling in HK‑2 cells."Int J Mol Med. 2019 Feb;43(2):709-716 52. [IF=1.146] Han Gao et al."Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali."Neuroreport. 2018 May 2; 29(7): 577–582 53. [IF=6.081] Tongji Liu et al."Improvement Effect of Lotus Leaf Flavonoids on Carbon Tetrachloride-Induced Liver Injury in Mice."Biomedicines. 2020 Feb;8(2):41 54. [IF=4.36] Pin Gong et al."Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway."J Ethnopharmacol. 2021 Dec;281:114558 55. [IF=4.225] Zhang Wei et al."Five Active Components Compatibility of Astragali Radix and Angelicae Sinensis Radix Protect Hematopoietic Function Against Cyclophosphamide-Induced Injury in Mice and t-BHP–Induced Injury in HSCs."Front Pharmacol. 2019 Aug;0:936 56. [IF=3.935] Yu-li Jiang et al."HPLC fingerprinting-based multivariate analysis of chemical components in Tetrastigma Hemsleyanum Diels et Gilg: Correlation to their antioxidant and neuraminidase inhibition activities."J Pharmaceut Biomed. 2021 Oct;205:114314 57. [IF=3.882] Kunpeng Yin et al."Lanthanide Metal–Organic Framework-Based Fluorescent Sensor Arrays to Discriminate and Quantify Ingredients of Natural Medicine."Langmuir. 2021;37(17):5321–5328 58. [IF=3.7] Jing-Jing Yang et al."Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells."Nutr Metab Cardiovas. 2020 May;30:829 59. [IF=3.69] Xiaoping Wang et al."Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats."J Ethnopharmacol. 2020 Apr;252:112536 60. [IF=3.69] Jingyi Hu et al."Qingchang Huashi Formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function."J Ethnopharmacol. 2021 Feb;266:113394 61. [IF=3.434] Du Xiaoxun et al."Tanshinone IIA and Astragaloside IV Inhibit miR-223/JAK2/STAT1 Signalling Pathway to Alleviate Lipopolysaccharide-Induced Damage in Nucleus Pulposus Cells."Dis Markers. 2021;2021:6554480 62. [IF=3.098] Haifeng Jin et al."Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling."Int J Mol Med. 2021 Feb;47(2):595-606 63. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950 64. [IF=1.662] Hui Shi et al."Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway."J Food Biochem. 2021 Jul;45(7):e13757 65. [IF=4.432] Hua Tian et al."Astragaloside IV protects against C/EBP homologous protein-mediated apoptosis in oxidized low-density lipoprotein-treated macrophages by promoting autophagy."Eur J Pharmacol. 2022 Mar;:174912 66. [IF=3.168] Yuqiong Lin et al."Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways."Diabet Metab Synd Ob. 2022 Jan;15:131-140 67. [IF=4.451] Liang Wang et al."Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway."J Funct Foods. 2022 Jan;88:104905 68. [IF=4.769] Xinyi Chai et al."Screening of immune cell activators from Astragali Radix using a comprehensive two-dimensional NK-92MI cell membrane chromatography/C18 column/time-of-flight mass spectrometry system."Journal of Pharmaceutical Analysis. 2022 May;: |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!